{"id":642253,"date":"2023-03-13T16:54:02","date_gmt":"2023-03-13T16:54:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=642253"},"modified":"2023-03-13T16:54:02","modified_gmt":"2023-03-13T16:54:02","slug":"rna-pipeline-constitutes-85-key-companies-continuously-working-towards-developing-100-rna-treatment-therapies-analyzes-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rna-pipeline-constitutes-85-key-companies-continuously-working-towards-developing-100-rna-treatment-therapies-analyzes-delveinsight_642253.html","title":{"rendered":"RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1678699027.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1678699027.jpeg\" alt=\"RNA pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA treatment therapies, analyzes DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>RNA pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsights,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/rna-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">RNA Competitive landscape, 2023<\/a>&rdquo;<\/strong>&nbsp;report provides comprehensive insights about&nbsp;<strong>85+ companies and 100+ RNA drugs<\/strong>&nbsp;in the RNA Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Ribonucleic acid (abbreviated RNA) is a nucleic acid present in all living cells that has structural similarities to DNA. Unlike DNA, however, RNA is most often single-stranded. An RNA molecule has a backbone made of alternating phosphate groups and the sugar ribose, rather than the deoxyribose found in DNA.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the RNA Pipeline Analysis report, click here:&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/rna-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">RNA Competitive landscape<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the RNA Competitive landscape report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Leading RNA Companies working in the market are Alnylam Pharmaceuticals, Suzhou Ribo Life Sciences, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Aro Biotherapeutics and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Key RNA therapies in various stages of development include Fitusiran, ARO-APOC3, LY3561774, DCR-HBVS, VIR-2218, Zilebesiran, OLX 101A and Others.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>In November 2021, Arrowhead Pharmaceuticals announced that it entered into an exclusive license agreement with GSK under which GSK will develop and commercialize ARO-HSD.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s RNA Report covers around 100+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by RNA Product Type<\/li>\n<li>Assessment by Stage and Product Type of RNA<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration of RNA<\/li>\n<li>Assessment by RNA Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type of RNA<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging RNA Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the RNA therapies are Vutrisiran, OLX 101A and Many Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further RNA product details are provided in the report. Download the RNA Pipeline report to learn more about the emerging RNA therapies at:&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rna-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/rna-competitive-landscape<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies in the RNA Therapeutics Market:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the RNA Companies working in the market are Alnylam Pharmaceuticals, Suzhou Ribo Life Sciences, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Aro Biotherapeutics and Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report to know in detail about the recent developments&nbsp; and advancements in RNA clinical trials &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rna-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><em>Phases of RNA Drugs in Pipeline<\/em><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. RNA Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. RNA Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. RNA Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. RNA Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. RNA Pipeline: Late Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. RNA Pipeline: Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">8. RNA Pipeline: Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">9. RNA Pipeline: Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">10. RNA Pipeline Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the RNA Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key RNA Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the RNA Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. RNA Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about @&nbsp;<\/strong><em><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rna-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">RNA drugs and medication<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=rna-pipeline-constitutes-85-key-companies-continuously-working-towards-developing-100-rna-treatment-therapies-analyzes-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=rna-pipeline-constitutes-85-key-companies-continuously-working-towards-developing-100-rna-treatment-therapies-analyzes-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>RNA pipeline DelveInsights,&nbsp;&ldquo;RNA Competitive landscape, 2023&rdquo;&nbsp;report provides comprehensive insights about&nbsp;85+ companies and 100+ RNA drugs&nbsp;in the RNA Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/rna-pipeline-constitutes-85-key-companies-continuously-working-towards-developing-100-rna-treatment-therapies-analyzes-delveinsight_642253.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-642253","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=642253"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=642253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=642253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=642253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}